ArticleScientific reports2018
Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 55 citations in OpenAlex.
- Inside the 'self-driving' lab revolution.Nature · 2026Article
- Contact-mediated triclosan delivery for transmission blocking ofFrontiers in microbiology · 2026Article
- Design and syntheses of 4-aminoquinoline-thiazolidinone hybrids as anti-protozoal agents.Frontiers in chemistry · 2026Article
- Automating the practice of science: Opportunities, challenges, and implications.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Harnessing computational methods for uncovering structural insights intoIn silico pharmacology · 2025Article
- To quest new targets ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Review
- Article
- In Silico Studies of Four Compounds ofMolecules (Basel, Switzerland) · 2023Article
- Geo-environmental factors and the effectiveness of mulberry leaf extract in managing malaria.Scientific reports · 2023Article
- Triclosan: A Small Molecule with Controversial Roles.Antibiotics (Basel, Switzerland) · 2022Review
- Identification of Growth Inhibitors of the Fish PathogenFrontiers in microbiology · 2020Article
- Antimalarial Properties of Isoquinoline Derivative fromBioMed research international · 2020Article
- Biochemical and Structural Insights Concerning Triclosan Resistance in a Novel YXScientific reports · 2019Article
- High-performance medicine: the convergence of human and artificial intelligence.Nature medicine · 2019Review
- Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells.OncoTargets and therapy · 2018Article
- Assessing the Risks Posed by the Convergence of Artificial Intelligence and Biotechnology.Health securityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
Malaria, caused by parasites of the genus Plasmodium, leads to over half a million deaths per year, 90% of which are caused by Plasmodium falciparum. P. vivax usually causes milder forms of malaria; however, P. vivax can remain dormant in the livers of infected patients for weeks or years before re-emerging in a new bout of the disease. The only drugs available that target all stages of the parasite can lead to severe side effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; hence, there is an urgent need to develop new drugs active against blood and liver stages of the parasite. Different groups have demonstrated that triclosan, a common antibacterial agent, targets the Plasmodium liver enzyme enoyl reductase. Here, we provide 4 independent lines of evidence demonstrating that triclosan specifically targets both wild-type and pyrimethamine-resistant P. falciparum and P. vivax dihydrofolate reductases, classic targets for the blood stage of the parasite. This makes triclosan an exciting candidate for further development as a dual specificity antimalarial, which could target both liver and blood stages of the parasite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.